Clinically relevant differences between the statins: implications for therapeutic selection.
about
Do statins reduce hepatitis C RNA titers during routine clinical use?Primary prevention of coronary heart disease in the elderlySecondary prevention of coronary heart disease in the elderlyPolymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicityDisorders of lipid metabolism and chronic kidney disease in the elderlyEffects of exercise training on mitochondrial function in patients with type 2 diabetes.Semisynthesis of novel monacolin J derivatives: hypocholesterolemic and neuroprotective activities.Association of pre-transplant statin use with delayed graft function in kidney transplant recipientsPopulation pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records.Statins: balancing benefits, efficacy and safety.Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practicesLack of therapeutic interchangeability of HMG-CoA reductase inhibitors.HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats.Antihypertensive therapy: special focus on drug interactions.Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone ratsStatins and liver toxicity: a meta-analysis.Statin-associated peripheral neuropathy: review of the literature.Treatment of dyslipidaemia in HIV-infected persons.Neuroinflammation: a potential therapeutic target.Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Clinical implications of pharmacogenomics of statin treatment.Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination.Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider.How is the heart best protected in chronic dialysis patients?: Between Scylla and Charybdis: what is the appropriate role for percutaneous coronary revascularization and coronary artery bypass grafting in patients on dialysis?Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Systematic review of red yeast rice compared with simvastatin in dyslipidaemia.Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis.Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.Differences in antitumor effects of various statins on human pancreatic cancer.Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts.Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats.Simvastatin-fluconazole causing rhabdomyolysis.Statins and modulation of oxidative stress.Fluvastatin-induced rhabdomyolysis.Causal structures for evaluating statin class effects.Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients.Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors.Predicted cardiovascular risk in HIV-infected patients.Adverse events with concomitant amiodarone and statin therapy.
P2860
Q27490248-ACAB5282-E64C-4D2B-A0D7-24794BF870DFQ28165739-D05118A2-7ECE-46F6-846F-953D7C6BB59BQ28166213-4800F52F-FD28-4547-8605-632BFF0958ADQ28480419-83968E61-247D-4C11-AF25-0C201363F744Q33589563-9044B812-9C53-4967-9F8D-4FDECA048CA7Q34023559-E56FB391-2BBA-4C4C-AE05-44709BA3C3BFQ34127245-2A137F3C-91B7-4FFC-A35B-7DAD677A12A5Q34416634-EA388ECC-16A5-484A-AD68-60AEE06947B0Q34554435-07F6E967-1433-4C20-BA57-781251D4D840Q34628565-9D1FAB4A-BC56-4611-AF50-F900D82878ACQ34874757-3A277624-B560-4112-8ADF-F21C9B3F3FAEQ35009456-7C495A24-7664-471B-A719-B14B7B380CAAQ35052776-13C8FDE7-E010-4CB7-BF72-9E6F34CB3867Q35570981-7283C23B-B593-45EC-BFDF-48538F17F2ABQ35691575-84919077-9E89-436C-8790-073A3D15FCE3Q35783702-E018693C-2CA8-4E57-AFB3-AE7453ADA346Q35906324-C54D67B0-8408-4591-89DD-236E1F8D8361Q36222023-1A931B4E-B63F-4147-B24E-5CE2E095DA6DQ36268282-A7072C4E-F3C1-4411-949D-611A799E4650Q36288839-5AE7AA33-345A-4031-8D28-FE3F68B2A733Q36426816-5F34E2FC-822E-4EE5-926C-3CC7858278E6Q37575362-B4B51C43-B33E-4FB7-AA13-4FB17D9CC4DFQ37765899-64CC28F8-65E5-4C01-BD51-C0193B1EE73FQ37801334-08FCCE7E-465F-4BA9-9C3C-4090DE45A14FQ38179487-02EEA6F3-BF78-40C7-8108-8CCB1B1B0A1AQ38663481-E05D68C7-2FD3-4CC5-9C46-397CC0A0DD40Q38766010-250993A2-1FF4-4EF9-8741-58F9B15AE7CDQ38853504-0F4DDF38-B650-47FC-82DF-CA89DA726B68Q39109470-B6789A07-22B7-49FE-9183-5865AEE80701Q40047633-F679671C-3D13-447D-ABED-31E076B4D13CQ41084475-6FD28E7C-D11E-4B0F-963D-591ECFA7FDF3Q41906208-D29281D1-AE5F-4F36-B051-51EEF70617C3Q42166140-84218FAE-8D99-4DD7-A453-2DDCE2E95EB2Q43215640-AC24B7B8-68AC-4E14-A004-D9DCFE1C7922Q44229921-F0E619C3-9C04-4928-9FD6-DEFCF6D8F909Q44258134-1E14AE3C-59FF-456F-B689-7C5675249C31Q44530977-6903E705-E53E-418E-9391-42F661D52600Q44846597-36FCF58F-B3F1-49C8-978C-937D87DEDDB3Q46081298-7CFBD4C8-D21E-4778-A235-9280EDA0B950Q46463293-78A7EFC2-9487-475C-B28F-B7BF1772CD3C
P2860
Clinically relevant differences between the statins: implications for therapeutic selection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinically relevant difference ...... ons for therapeutic selection.
@ast
Clinically relevant difference ...... ons for therapeutic selection.
@en
Clinically relevant difference ...... ons for therapeutic selection.
@nl
type
label
Clinically relevant difference ...... ons for therapeutic selection.
@ast
Clinically relevant difference ...... ons for therapeutic selection.
@en
Clinically relevant difference ...... ons for therapeutic selection.
@nl
prefLabel
Clinically relevant difference ...... ons for therapeutic selection.
@ast
Clinically relevant difference ...... ons for therapeutic selection.
@en
Clinically relevant difference ...... ons for therapeutic selection.
@nl
P2093
P1476
Clinically relevant difference ...... ons for therapeutic selection.
@en
P2093
P304
P356
10.1016/S0002-9343(01)00870-1
P407
P577
2001-10-01T00:00:00Z